578 related articles for article (PubMed ID: 21591981)
1. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
2. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
[TBL] [Abstract][Full Text] [Related]
3. PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors.
Glenn JR; White AE; Iyu D; Heptinstall S
Platelets; 2012; 23(5):344-51. PubMed ID: 22436052
[TBL] [Abstract][Full Text] [Related]
4. The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.
Xiang B; Zhang G; Ren H; Sunkara M; Morris AJ; Gartner TK; Smyth SS; Li Z
PLoS One; 2012; 7(12):e51037. PubMed ID: 23236426
[TBL] [Abstract][Full Text] [Related]
5. DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease.
Heptinstall S; Espinosa DI; Manolopoulos P; Glenn JR; White AE; Johnson A; Dovlatova N; Fox SC; May JA; Hermann D; Magnusson O; Stefansson K; Hartman D; Gurney M
Platelets; 2008 Dec; 19(8):605-13. PubMed ID: 19012178
[TBL] [Abstract][Full Text] [Related]
6. Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers.
Fox SC; May JA; Johnson A; Hermann D; Strieter D; Hartman D; Heptinstall S
Platelets; 2013; 24(5):392-400. PubMed ID: 22866894
[TBL] [Abstract][Full Text] [Related]
7. PGE1 and PGE2 modify platelet function through different prostanoid receptors.
Iyú D; Jüttner M; Glenn JR; White AE; Johnson AJ; Fox SC; Heptinstall S
Prostaglandins Other Lipid Mediat; 2011 Feb; 94(1-2):9-16. PubMed ID: 21095237
[TBL] [Abstract][Full Text] [Related]
8. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
Pampuch A; Cerletti C; de Gaetano G
Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
[TBL] [Abstract][Full Text] [Related]
9. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
Iyú D; Glenn JR; White AE; Fox SC; Heptinstall S
Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):416-22. PubMed ID: 21106949
[TBL] [Abstract][Full Text] [Related]
10. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
Judge HM; Buckland RJ; Sugidachi A; Jakubowski JA; Storey RF
Platelets; 2008 Mar; 19(2):125-33. PubMed ID: 18297550
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
[TBL] [Abstract][Full Text] [Related]
13. Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents.
Manolopoulos P; Glenn JR; Fox SC; May JA; Dovlatova NL; Tang SW; Thomas NR; Ralevic V; Heptinstall S
Platelets; 2008 Mar; 19(2):134-45. PubMed ID: 18297551
[TBL] [Abstract][Full Text] [Related]
14. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
[TBL] [Abstract][Full Text] [Related]
16. Prostacyclin receptor stimulation facilitates detection of human platelet P2Y(12) receptor inhibition by the PFA-100 system.
Kobsar AL; Koessler J; Rajkovic MS; Brunner KP; Steigerwald U; Walter U
Platelets; 2010; 21(2):112-6. PubMed ID: 20085435
[TBL] [Abstract][Full Text] [Related]
17. 'VASPFix' for measurement of VASP phosphorylation in platelets and for monitoring effects of P2Y12 antagonists.
Glenn JR; Dovlatova N; White AE; Dhillon K; Heptinstall S; Fox SC
Thromb Haemost; 2014 Mar; 111(3):539-48. PubMed ID: 24258486
[TBL] [Abstract][Full Text] [Related]
18. The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y₁₂ receptor inhibition.
Koessler J; Kobsar AL; Rajkovic MS; Schafer A; Flierl U; Pfoertsch S; Bauersachs J; Steigerwald U; Rechner AR; Walter U
Platelets; 2011; 22(1):20-7. PubMed ID: 20873965
[TBL] [Abstract][Full Text] [Related]
19. Platelets Express Activated P2Y
Hu L; Chang L; Zhang Y; Zhai L; Zhang S; Qi Z; Yan H; Yan Y; Luo X; Zhang S; Wang Y; Kunapuli SP; Ye H; Ding Z
Circulation; 2017 Aug; 136(9):817-833. PubMed ID: 28637879
[TBL] [Abstract][Full Text] [Related]
20. Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors.
Petrucci G; De Cristofaro R; Rutella S; Ranelletti FO; Pocaterra D; Lancellotti S; Habib A; Patrono C; Rocca B
J Pharmacol Exp Ther; 2011 Feb; 336(2):391-402. PubMed ID: 21059804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
